The article published on Monday focused on the company Accelerated Evolution Biotechnologies Ltd. (Aebi).
"We believe we will provide a complete cure for cancer in a year's time," Dan Aridor, the company's CEO, quoted in the article.
The report said the treatment of the company was said: "MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a high-order disruption technology."
Despite the report, doctors who spoke with ABC11 in North Carolina expressed skepticism about the claims. [1
Off-camera, a spokesperson for Duke Health, declined to comment on the report. He mentioned the lack of a scientific peer review and called it a "non-story".
"I really think it is really unfair and almost cruel to say that these are probably false hopes for cancer patients," Dr. Neel.
The Jerusalem Post article reports that the company has tested mice and is facing clinical trials. 19659003] "As far as I know, this product was not available to patients, and the story is full of claims based on test tube or animal studies that absolutely could not be translated to human disease," Dr. Neel.
In a statement to our sister station ABC11, Aridor said that AEBi had no university research publishing for peer review: Aridor pointed out that the company held three drug discovery conferences in 2017 and 2018 (two in Germany, one in Boston) gave extensive lectures on his progress and lessons learned, adding that it received "wonderful reviews."  "If they submit it for review and are published in a prestigious journal, and we can look at it, it will be a different story," Neel said.
AEBi received a US patent on its platform last month.
Aridor is quoted in the Jerusalem Post article as "Our Solution Will Be Both General and Personal"
The National Cancer Institute estimated that more than 1.7 million people by 2018 Cancer would be ill and this year more than 600,000 would die from the disease.
Follow us on YouTube
Submit a News Tip Action News
Learn more about 6abc apps
(Copyright © 2019 WPVI-TV.) All rights reserved. )